Clinical Efficacy of PD-1 Inhibitors Plus Split-Course Radiotherapy in the First-Line Treatment of Advanced Kidney Cancer: A Randomized Controlled Trial

Table 3

Comparison of PFS.

	Events	Median	0.95 LCL	0.95 UCL
Control group (n = 22)	16	21.5	14.1	NA
Study group (n = 22)	11	28.1	24.5	NA
HR (95% CI)	1.875 (0.877–4.011)
	0.104